| For: | Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 2009; 15(46): 5867-5870 [PMID: 19998512 DOI: 10.3748/wjg.15.5867] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i46/5867.htm |
| Number | Citing Articles |
| 1 |
T.W. Barber, M.S. Hofman, B.N.J. Thomson, R.J. Hicks. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. European Journal of Surgical Oncology (EJSO) 2012; 38(1) doi: 10.1016/j.ejso.2011.08.129
|
| 2 |
George Barberio Coura-Filho, Mayara Torres Silva de Oliveira, Ana Luiza Morais de Campos. Nuklearmedizin bei endokrinen Erkrankungen. 2024; doi: 10.1007/978-3-031-47988-5_32
|
| 3 |
Beata Jabłońska, Daria Dranka-Bojarowska, Hanna Palacz, Adam Lewiński, Paweł Lampe. Surgical Treatment of Pancreatic Neuroendocrine Tumours - Clinical Experience. Polish Journal of Surgery 2011; 83(4) doi: 10.2478/v10035-011-0033-5
|
| 4 |
Giorgia Ricciardello, Greta Celesti, Matteo Bauckneht, Irene A. Burger, Andrei Iagaru, Martina Arco, Sabrina Curatolo, Benedetta Pagano, Ernesto Amato, Lucrezia Auditore, Luca Fiorillo, Antonio Piras, Leandra Piscopo, Ahmad Shariftabrizi, Massimiliano Berretta, Sergio Lucio Vinci, Fabio Minutoli, Riccardo Laudicella. Is there a role for early SSTR-targeting PRRT in GEP-NET?. European Journal of Nuclear Medicine and Molecular Imaging 2026; doi: 10.1007/s00259-026-07974-4
|
| 5 |
Giuseppe Lo Russo, Sara Pusceddu, Natalie Prinzi, Martina Imbimbo, Claudia Proto, Diego Signorelli, Milena Vitali, Monica Ganzinelli, Marco Maccauro, Roberto Buzzoni, Ettore Seregni, Filippo de Braud, Marina Chiara Garassino. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. Tumor Biology 2016; 37(10) doi: 10.1007/s13277-016-5258-9
|
| 6 |
Jaume Capdevila, Enrique Grande, Rocío García-Carbonero, Marc Simó, Mª Isabel del Olmo-García, Paula Jiménez-Fonseca, Alberto Carmona-Bayonas, Virginia Pubul. Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. The Oncologist 2022; 27(4) doi: 10.1093/oncolo/oyab041
|
| 7 |
Tessa Brabander, Jaap J.M. Teunissen, Casper H.J. Van Eijck, Gaston J.H. Franssen, Richard A. Feelders, Wouter W. de Herder, Dik J. Kwekkeboom. Peptide receptor radionuclide therapy of neuroendocrine tumours. Best Practice & Research Clinical Endocrinology & Metabolism 2016; 30(1) doi: 10.1016/j.beem.2015.10.005
|
| 8 |
Cyprian Świętaszczyk, Vikas Prasad, Richard P. Baum. Intense 18F-Fluoride Accumulation in Liver Metastases From a Neuroendocrine Tumor After Peptide Receptor Radionuclide Therapy. Clinical Nuclear Medicine 2012; 37(4) doi: 10.1097/RLU.0b013e3182478a50
|
| 9 |
Richard P. Baum, Harshad R. Kulkarni, Cecilia Carreras. Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms. Seminars in Nuclear Medicine 2012; 42(3) doi: 10.1053/j.semnuclmed.2012.01.002
|
| 10 |
M Shah, R Da Silva, C Gravekamp, S K Libutti, T Abraham, E Dadachova. Targeted radionuclide therapies for pancreatic cancer. Cancer Gene Therapy 2015; 22(8) doi: 10.1038/cgt.2015.32
|
| 11 |
Michael Gabriel. Radiopeptidtherapie – der „Mustang“ in der Therapie von neuroendokrinen Tumoren des gastroentero-pankreatischen Systems?. Journal für Klinische Endokrinologie und Stoffwechsel 2018; 11(3) doi: 10.1007/s41969-018-0034-7
|
| 12 |
Nader Hirmas, Raya Jadaan, Akram Al-Ibraheem. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives. Nuclear Medicine and Molecular Imaging 2018; 52(3) doi: 10.1007/s13139-018-0517-x
|
| 13 |
Iraklis Perysinakis, Chrysanthi Aggeli, Gregory Kaltsas, George N. Zografos. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?. Hormones 2016; 15(1) doi: 10.1007/BF03401399
|
| 14 |
Costanza Chiapponi, Nadine Lürssen, Birgit Cremer, Roger Wahba, Uta Drebber, Michael Faust, Matthias Schmidt, Dirk L. Stippel. Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experience. Endocrine 2020; 70(1) doi: 10.1007/s12020-020-02341-1
|
| 15 |
Kotaro Sakaki, Mitsuru Chiba, Katsunori Iijima, Takashi Goto, Junichi Arita, Hidehiko Tsuda. Grade 3 Pancreatic Neuroendocrine Tumor Refractory to Chemotherapy Successfully Treated with Peptide Receptor Radionuclide Therapy Leading to Conversion Surgery. Internal Medicine 2025; 64(5) doi: 10.2169/internalmedicine.3768-24
|
| 16 |
Hendrik Bergsma, Esther I. van Vliet, Jaap J.M. Teunissen, Boen L.R. Kam, Wouter W. de Herder, Robin P. Peeters, Eric P. Krenning, Dik J. Kwekkeboom. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Practice & Research Clinical Gastroenterology 2012; 26(6) doi: 10.1016/j.bpg.2013.01.004
|
| 17 |
Mila Todorović-Tirnanić, Daniel Kaemmerer, Vikas Prasad, Merten Hommann, Richard P. Baum. Theranostics, Gallium-68, and Other Radionuclides. Recent Results in Cancer Research 2013; 194 doi: 10.1007/978-3-642-27994-2_28
|
| 18 |
Sze Ting Lee, Harshad R. Kulkarni, Aviral Singh, Richard P. Baum. Theranostics of Neuroendocrine Tumors. Visceral Medicine 2017; 33(5) doi: 10.1159/000480383
|
| 19 |
Joanne S. Evans, Jamie Beaumont, Marta Braga, Nahal Masrour, Francesco Mauri, Alice Beckley, Shamus Butt, Christina S. Karali, Chris Cawthorne, Stephen Archibald, Eric O. Aboagye, Rohini Sharma. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy. European Journal of Cancer 2022; 176 doi: 10.1016/j.ejca.2022.09.009
|
| 20 |
Richard P Baum, Harshad R Kulkarni. Molecular Imaging using PET/CT Applying 68Ga-Labeled Tracers and Targeted Radionuclide Therapy: Theranostics on the Way to Personalized Medicine. Journal of Postgraduate Medicine, Education and Research 2013; 47(1) doi: 10.5005/jp-journals-10028-1055
|
| 21 |
Sander M. Bison, Mark W. Konijnenberg, Marleen Melis, Stefan E. Pool, Monique R. Bernsen, Jaap J. M. Teunissen, Dik J. Kwekkeboom, Marion de Jong. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clinical and Translational Imaging 2014; 2(1) doi: 10.1007/s40336-014-0054-2
|
| 22 |
Francesca Muffatti, Mauro Cives, Stefano Partelli, Franco Silvestris, Massimo Falconi. Neuroendocrine Tumors in Real Life. 2018; doi: 10.1007/978-3-319-59024-0_17
|
| 23 |
Andrea Frilling, Irvin M Modlin, Mark Kidd, Christopher Russell, Stefan Breitenstein, Riad Salem, Dik Kwekkeboom, Wan-yee Lau, Catherine Klersy, Valerie Vilgrain, Brian Davidson, Mark Siegler, Martyn Caplin, Enrico Solcia, Richard Schilsky. Recommendations for management of patients with neuroendocrine liver metastases. The Lancet Oncology 2014; 15(1) doi: 10.1016/S1470-2045(13)70362-0
|
| 24 |
Luca Urso, Alberto Nieri, Ilaria Rambaldi, Angelo Castello, Licia Uccelli, Corrado Cittanti, Stefano Panareo, Irene Gagliardi, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Mirco Bartolomei. Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review. Endocrine 2022; 78(2) doi: 10.1007/s12020-022-03170-0
|
| 25 |
Tanaz Vaghaiwalla, Brian Ruhle, Kelvin Memeh, Peter Angelos, Edwin Kaplan, Chih-Yi Liao, Blase Polite, Xavier Keutgen. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery 2021; 169(1) doi: 10.1016/j.surg.2020.04.001
|
| 26 |
Ryosuke Umino, Satoshi Nara, Noritoshi Kobayashi, Takahiro Mizui, Takeshi Takamoto, Daisuke Ban, Minoru Esaki, Nobuyoshi Hiraoka, Kazuaki Shimada. Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report. Surgical Case Reports 2024; 10(1) doi: 10.1186/s40792-024-01839-4
|
| 27 |
B. L. R. Kam, J. J. M. Teunissen, E. P. Krenning, W. W. de Herder, S. Khan, E. I. van Vliet, D. J. Kwekkeboom. Lutetium-labelled peptides for therapy of neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2012; 39(S1) doi: 10.1007/s00259-011-2039-y
|
| 28 |
Ashley Kieran Clift, Mark Kidd, Lisa Bodei, Christos Toumpanakis, Richard P. Baum, Kjell Oberg, Irvin M. Modlin, Andrea Frilling. Neuroendocrine Neoplasms of the Small Bowel and Pancreas. Neuroendocrinology 2020; 110(6) doi: 10.1159/000503721
|
| 29 |
Pamela Moyade, Sobhan Vinjamuri. The heart matters. Nuclear Medicine Communications 2019; 40(10) doi: 10.1097/MNM.0000000000001064
|
| 30 |
Amir Sabet, Hans-Jürgen Biersack, Samer Ezziddin. Advances in Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine 2016; 46(1) doi: 10.1053/j.semnuclmed.2015.09.005
|
| 31 |
Eric H. Liu, Irvin Modlin. Therapeutic Nuclear Medicine. Medical Radiology 2013; doi: 10.1007/174_2013_808
|
| 32 |
Yongzheng Li, Zhiyao Fan, Feifei Zhang, Jian Yang, Ming Shi, Shujie Liu, Yufan Meng, Hanxiang Zhan. Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.981575
|
| 33 |
Mitesh Naik, Adil Al-Nahhas, Sairah R. Khan. Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now. Cancers 2022; 14(3) doi: 10.3390/cancers14030761
|
| 34 |
George Barberio Coura-Filho, Mayara Torres Silva de Oliveira, Ana Luiza Morais de Campos. Nuclear Medicine in Endocrine Disorders. 2022; doi: 10.1007/978-3-031-13224-7_32
|
| 35 |
Andrea Frilling, Ashley K. Clift. Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. 2024; doi: 10.1007/978-3-031-33533-4_3
|
| 36 |
Sandip Basu, Vikas Ostwal, Rohit Ranade, Dipanjan Panda. Supportive Measures and Finer Practice Points in 177Lu-DOTATATE PRRT for NET: Aiming for Optimal Disease Management. Journal of Nuclear Medicine 2014; 55(11) doi: 10.2967/jnumed.114.146282
|
| 37 |
Anna Sowa-Staszczak, Dorota Pach, Robert Chrzan, Małgorzata Trofimiuk, Agnieszka Stefańska, Monika Tomaszuk, Maciej Kołodziej, Renata Mikołajczak, Dariusz Pawlak, Alicja Hubalewska-Dydejczyk. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). European Journal of Nuclear Medicine and Molecular Imaging 2011; 38(9) doi: 10.1007/s00259-011-1835-8
|
| 38 |
Rejoice Ngongoni, Brendan Visser. Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases. Cancers 2022; 14(20) doi: 10.3390/cancers14205103
|
| 39 |
|
| 40 |
Anna Sowa-Staszczak, Robert Chrzan, Dorota Pach, Agnieszka Stefańska, Monika Tomaszuk, Monika Buziak-Bereza, Maciej Kołodziej, Elwira Przybylik-Mazurek, Alicja Hubalewska-Dydejczyk. Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?. Clinical Imaging 2012; 36(4) doi: 10.1016/j.clinimag.2011.11.005
|
| 41 |
Dik J. Kwekkeboom, Eric P. Krenning. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematology/Oncology Clinics of North America 2016; 30(1) doi: 10.1016/j.hoc.2015.09.009
|
| 42 |
Marianne Pavel, Eric Baudin, Anne Couvelard, Eric Krenning, Kjell Öberg, Thomas Steinmüller, Martin Anlauf, Bertram Wiedenmann, Ramon Salazar. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary. Neuroendocrinology 2012; 95(2) doi: 10.1159/000335597
|
| 43 |
Tak Geun Oh, Moon Jae Chung, Jeong Yeop Park, Seung Min Bang, Seung Woo Park, Jae Bok Chung, Si Young Song. Prognostic Factors and Characteristics of Pancreatic Neuroendocrine Tumors: Single Center Experience. Yonsei Medical Journal 2012; 53(5) doi: 10.3349/ymj.2012.53.5.944
|
| 44 |
Daniel Kaemmerer, Ralph M. Wirtz, Elke K. Fischer, Merten Hommann, Jörg Sänger, Vikas Prasad, Elisa Specht, Richard P. Baum, Stefan Schulz, Amelie Lupp. Analysis of Somatostatin Receptor 2A Immunohistochemistry, RT-qPCR, and In Vivo PET/CT Data in Patients With Pancreatic Neuroendocrine Neoplasm. Pancreas 2015; 44(4) doi: 10.1097/MPA.0000000000000316
|
| 45 |
Jordan M. Cloyd, Kiyohiko Omichi, Takashi Mizuno, Yoshikuni Kawaguchi, Ching-Wei D. Tzeng, Claudius Conrad, Yun Shin Chun, Thomas A. Aloia, Matthew H. G. Katz, Jeffrey E. Lee, Daniel Halperin, James Yao, Jean-Nicolas Vauthey, Arvind Dasari. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Annals of Surgical Oncology 2018; 25(6) doi: 10.1245/s10434-018-6468-8
|
| 46 |
S. Gül-Klein, R. Schmuck, D. P. Modest, J. Pratschke. Therapie kolorektaler und nichtkolorektaler Lebermetastasen: Sinnhaftigkeit neoadjuvanter Therapiekonzepte. Der Chirurg 2020; 91(5) doi: 10.1007/s00104-020-01133-7
|
| 47 |
Hina J. Shah, Evan Ruppell, Rozan Bokhari, Parag Aland, Vikram R. Lele, Connie Ge, Lacey J. McIntosh. Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review. European Journal of Radiology Open 2023; 10 doi: 10.1016/j.ejro.2023.100477
|
| 48 |
Anna Sowa-Staszczak, Alicja Hubalewska-Dydejczyk, Monika Tomaszuk. Theranostics, Gallium-68, and Other Radionuclides. Recent Results in Cancer Research 2013; 194 doi: 10.1007/978-3-642-27994-2_27
|
| 49 |
Mauro Cives, Jonathan Strosberg. Radionuclide Therapy for Neuroendocrine Tumors. Current Oncology Reports 2017; 19(2) doi: 10.1007/s11912-017-0567-8
|
| 50 |
Andrea Lania, Francesco Ferraù, Manila Rubino, Roberta Modica, Annamaria Colao, Antongiulio Faggiano. Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.651438
|
| 51 |
Marco Schiavo Lena, Stefano Partelli, Paola Castelli, Valentina Andreasi, Chanel Elisha Smart, Eleonora Pisa, Mirco Bartolomei, Emilio Bertani, Giuseppe Zamboni, Massimo Falconi, Claudio Doglioni. Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT). Endocrine Pathology 2020; 31(2) doi: 10.1007/s12022-020-09623-4
|
| 52 |
Richard P. Baum, Harshad R. Kulkarni. Therapeutic Nuclear Medicine. Medical Radiology 2014; doi: 10.1007/174_2013_945
|
| 53 |
Wouter A van der Zwan, Lisa Bodei, Jan Mueller-Brand, Wouter W de Herder, Larry K Kvols, Dik J Kwekkeboom. GEP–NETs UPDATE: Radionuclide therapy in neuroendocrine tumors. European Journal of Endocrinology 2015; 172(1) doi: 10.1530/EJE-14-0488
|
| 54 |
Esther I. van Vliet, Casper H. van Eijck, Ronald R. de Krijger, Elisabeth J. Nieveen van Dijkum, Jaap J. Teunissen, Boen L. Kam, Wouter W. de Herder, Richard A. Feelders, Bert A. Bonsing, Tessa Brabander, Eric P. Krenning, Dik J. Kwekkeboom. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate. Journal of Nuclear Medicine 2015; 56(11) doi: 10.2967/jnumed.115.158899
|
| 55 |
K.L. Pomykala, B.A. Hadaschik, O. Sartor, S. Gillessen, C.J. Sweeney, T. Maughan, M.S. Hofman, K. Herrmann. Next generation radiotheranostics promoting precision medicine. Annals of Oncology 2023; 34(6) doi: 10.1016/j.annonc.2023.03.001
|
| 56 |
Simone Krebs, Mark Dunphy. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. 2017; doi: 10.1016/B978-0-323-34062-5.00017-0
|
| 57 |
Ashley K. Clift, Henk Giele, Srikanth Reddy, Rubens Macedo, Adil Al-Nahhas, Harpreet S. Wasan, Gabriel E. Gondolesi, Rodrigo M. Vianna, Peter Friend, Anil Vaidya, Andrea Frilling. Neoadjuvant peptide receptor radionuclide therapy and modified multivisceral transplantation for an advanced small intestinal neuroendocrine neoplasm: an updated case report. Innovative Surgical Sciences 2017; 2(4) doi: 10.1515/iss-2017-0025
|
| 58 |
Sandip Basu, Rahul V. Parghane, Vikas Ostwal, Shailesh V. Shrikhande. Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors. Nuclear Medicine Communications 2018; 39(1) doi: 10.1097/MNM.0000000000000776
|
| 59 |
Daniel Kaemmerer, Vikas Prasad, Wolfgang Daffner, Sven-Petter Haugvik, Stefan Senftleben, Richard P. Baum, Merten Hommann. Radioguided Surgery in Neuroendocrine Tumors Using Ga-68-Labeled Somatostatin Analogs. Clinical Nuclear Medicine 2012; 37(2) doi: 10.1097/RLU.0b013e3182291de8
|
| 60 |
Kelsey L. Pomykala, Ken Herrmann. Radiopharmaceutical Therapy. 2023; doi: 10.1007/978-3-031-39005-0_1
|
| 61 |
Raghava Kashyap, Senthil Raja, Ajay Adusumilli, Murali Mohan Reddy Gopireddy, Benjamin P. T. Loveday, Ramin Alipour, Grace Kong. Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro‐entero‐pancreatic neuroendocrine neoplasms: A scoping review. Journal of Neuroendocrinology 2025; 37(3) doi: 10.1111/jne.13425
|
| 62 |
Deborah Pencharz, Gopinath Gnanasegaran, Shaunak Navalkissoor. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. The British Journal of Radiology 2018; 91(1091) doi: 10.1259/bjr.20180108
|
| 63 |
Mengting Zhang, Lunan Wu, Lei Wu, Bingsong Yan. Clinical analysis of seven cases of primary hepatic neuroendocrine neoplasms. Frontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1729932
|
| 64 |
Andrea Frilling, Ashley K. Clift. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015; 121(8) doi: 10.1002/cncr.28760
|
| 65 |
Claudia Burkhardt, Léo Bühler, David Viertl, Thierry Stora. New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.674656
|
| 66 |
James R. Howe, Nipun B. Merchant, Claudius Conrad, Xavier M. Keutgen, Julie Hallet, Jeffrey A. Drebin, Rebecca M. Minter, Terry C. Lairmore, Jennifer F. Tseng, Herbert J. Zeh, Steven K. Libutti, Gagandeep Singh, Jeffrey E. Lee, Thomas A. Hope, Michelle K. Kim, Yusuf Menda, Thorvardur R. Halfdanarson, Jennifer A. Chan, Rodney F. Pommier. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020; 49(1) doi: 10.1097/MPA.0000000000001454
|
| 67 |
Ashley Kieran Clift, Andrea Frilling. Management of patients with hepatic metastases from neuroendocrine tumors. Annals of Saudi Medicine 2014; 34(4) doi: 10.5144/0256-4947.2014.279
|
| 68 |
Ashley Kieran Clift, Andrea Frilling. Neuroendocrine Tumors. 2021; doi: 10.1007/978-3-030-62241-1_17
|
| 69 |
S. Nadalin, M. Peters, A. Königsrainer. Lebermetastasen neuroendokriner Tumoren. Die Chirurgie 2022; 93(7) doi: 10.1007/s00104-022-01656-1
|
| 70 |
Isabella Zanata, Maria Rosaria Ambrosio, Maria Chiara Zatelli. Neoadjuvant PRRT for advanced pNEN: an unusual highlander. Endocrine 2021; 73(2) doi: 10.1007/s12020-021-02662-9
|
| 71 |
Daniel Kaemmerer. Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. 2024; doi: 10.1007/978-3-031-33533-4_17
|